Sorafenib is a new type of anti-cancer drug. It belongs to a new class of medications known
as tyrosine kinase inhibitors. Sorafenib is thought to work against cancer in many ways. It
helps decrease blood supply to the tumor. It also blocks some proteins that help the tumor
cells to grow." Sorafenib is approved by the Food and Drug administration (FDA) for treatment
for other cancers like liver and kidney cancer. Sorafenib has also been studied in the
treatment of breast cancer that has spread but is not specifically approved for the treatment
of breast cancer. It has been studied both as a single agent and also in combination with
other anti-cancer therapies for breast cancer. In laboratory models and in some patients with
other cancers, sorafenib has been studied in tumors in the brain.
In this study, sorafenib will be given together with whole brain radiation therapy (WBRT).
Overall this research study is designed to answer 2 main questions:
1. What dose of sorafenib should be used together with WBRT?
2. What are the side effects of sorafenib and WBRT when given together?